Oncotarget

Reviews:

Genetic association between PSA-158G/A polymorphism and the susceptibility of benign prostatic hyperplasia: a meta-analysis

Xin-Jun Su, Xian-Tao Zeng, Cheng Fang, Tong-Zu Liu and Xing-Huan Wang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:33953-33960. https://doi.org/10.18632/oncotarget.15424

Metrics: PDF 1619 views  |   HTML 2248 views  |   ?  


Abstract

Xin-Jun Su1,*, Xian-Tao Zeng1,2,3,*, Cheng Fang2, Tong-Zu Liu1 and Xing-Huan Wang1,2,3

1 Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China

2 Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China

3 Department of Evidence-Based Medicine and Clinical Epidemiology, The Second Clinical College, Wuhan University, Wuhan, China

* These authors have contributed equally to this work

Correspondence to:

Xing-Huan Wang, email:

Keywords: PSA, polymorphism, BPH, meta-analysis

Received: January 02, 2017 Accepted: February 08, 2017 Published: February 16, 2017

Abstract

Inconsistency between reported findings on the association of prostate specific antigen (PSA) gene -158G/A polymorphism with benign prostatic hyperplasia (BPH) susceptibility need a meta-analysis to obtain a more accurate conclusion. A systematic search was conducted in electronic databases for the collection of eligible studies on PSA -158G/A polymorphism and BPH susceptibility. Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were then calculated. 7 case-control studies with 758 cases and 752 controls were included into the present meta-analysis. The analysis results showed no significant relationship between PSA -158G/A polymorphism and BPH susceptibility in total analysis. Interestingly, after subgroup analyses based on ethnicity and source of control, the polymorphism reduced the susceptibility of BPH in Caucasian group (AA vs. GG: OR=0.47, 95% CI=0.25-0.89; allele A vs. allele G: OR=0.68, 95% CI=0.49-0.93), but it increased the disease susceptibility in Asian (AA vs. GG: OR=1.63, 95% CI=1.02-2.60; allele A vs. allele G: OR=1.37, 95% CI=1.03-1.83) and population-based (AA vs. GG: OR=2.39, 95% CI=1.07-5.38; allele A vs. allele G: OR=1.83, 95% CI=1.26-2.65) groups. PSA-158G/A polymorphism may be an inhibitor to the incidence of BPH in Caucasians, but it is likely to be a susceptible factor in Asians.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15424